<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Desert R</submitter><funding>European Research Council</funding><funding>NIDDK NIH HHS</funding><funding>U.S. Department of Defense</funding><funding>NCI NIH HHS</funding><pagination>692-709</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8948552</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(4)</volume><pubmed_abstract>Osteopontin (OPN) expression correlates with tumor progression in many cancers, including hepatocellular carcinoma (HCC); however, its role in the onset of HCC remains unclear. We hypothesized that increased hepatocyte-derived OPN is a driver of hepatocarcinogenesis. Analysis of a tissue microarray of 366 human samples revealed a continuous increase in OPN expression during hepatocarcinogenesis. In patients with cirrhosis, a transcriptome-based OPN correlation network was associated with HCC incidence along 10 years of follow-up, together with messenger RNA (mRNA) signatures of carcinogenesis. After diethylnitrosamine (DEN) injection, mice with conditional overexpression of Opn in hepatocytes (Opn&lt;sup>Hep&lt;/sup> transgenic [Tg]) showed increased tumor burden. Surprisingly, mice with conditional ablation of Opn in hepatocytes (Opn&lt;sup>ΔHep&lt;/sup> ) expressed a similar phenotype. The acute response to DEN was reduced in Opn&lt;sup>ΔHep&lt;/sup> , which also showed more cancer stem/progenitor cells (CSCs, CD44&lt;sup>+&lt;/sup> AFP&lt;sup>+&lt;/sup> ) at 5 months. CSCs from Opn&lt;sup>Hep&lt;/sup> Tg mice expressed several mRNA signatures known to promote carcinogenesis, and mRNA signatures from Opn&lt;sup>Hep&lt;/sup> Tg mice were associated with poor outcome in human HCC patients. Treatment with rOPN had little effect on CSCs, and their progression to HCC was similar in Opn&lt;sup>-/-&lt;/sup> compared with wild-type mice. Finally, ablation of Cd44, an OPN receptor, did not reduce tumor burden in Cd44&lt;sup>-/-&lt;/sup> Opn&lt;sup>Hep&lt;/sup> Tg mice. Conclusions: Hepatocyte-derived OPN acts as a tumor suppressor at physiological levels by controlling the acute response to DEN and the presence of CSCs, while induction of OPN is pro-tumorigenic. This is primarily due to intracellular events rather that by the secretion of the protein and receptor activation.</pubmed_abstract><journal>Hepatology communications</journal><pubmed_title>Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis.</pubmed_title><pmcid>PMC8948552</pmcid><funding_grant_id>R01 DK099558</funding_grant_id><funding_grant_id>671231</funding_grant_id><funding_grant_id>R01 CA233794</funding_grant_id><funding_grant_id>CA170172</funding_grant_id><pubmed_authors>Desert R</pubmed_authors><pubmed_authors>Das S</pubmed_authors><pubmed_authors>Musso O</pubmed_authors><pubmed_authors>Nieto N</pubmed_authors><pubmed_authors>Athavale D</pubmed_authors><pubmed_authors>Abraham-Enachescu I</pubmed_authors><pubmed_authors>Ge X</pubmed_authors><pubmed_authors>Lantvit D</pubmed_authors><pubmed_authors>Chen W</pubmed_authors><pubmed_authors>Han H</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Blajszczak C</pubmed_authors><pubmed_authors>Guzman G</pubmed_authors><pubmed_authors>Song Z</pubmed_authors><pubmed_authors>Hoshida Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis.</name><description>Osteopontin (OPN) expression correlates with tumor progression in many cancers, including hepatocellular carcinoma (HCC); however, its role in the onset of HCC remains unclear. We hypothesized that increased hepatocyte-derived OPN is a driver of hepatocarcinogenesis. Analysis of a tissue microarray of 366 human samples revealed a continuous increase in OPN expression during hepatocarcinogenesis. In patients with cirrhosis, a transcriptome-based OPN correlation network was associated with HCC incidence along 10 years of follow-up, together with messenger RNA (mRNA) signatures of carcinogenesis. After diethylnitrosamine (DEN) injection, mice with conditional overexpression of Opn in hepatocytes (Opn&lt;sup>Hep&lt;/sup> transgenic [Tg]) showed increased tumor burden. Surprisingly, mice with conditional ablation of Opn in hepatocytes (Opn&lt;sup>ΔHep&lt;/sup> ) expressed a similar phenotype. The acute response to DEN was reduced in Opn&lt;sup>ΔHep&lt;/sup> , which also showed more cancer stem/progenitor cells (CSCs, CD44&lt;sup>+&lt;/sup> AFP&lt;sup>+&lt;/sup> ) at 5 months. CSCs from Opn&lt;sup>Hep&lt;/sup> Tg mice expressed several mRNA signatures known to promote carcinogenesis, and mRNA signatures from Opn&lt;sup>Hep&lt;/sup> Tg mice were associated with poor outcome in human HCC patients. Treatment with rOPN had little effect on CSCs, and their progression to HCC was similar in Opn&lt;sup>-/-&lt;/sup> compared with wild-type mice. Finally, ablation of Cd44, an OPN receptor, did not reduce tumor burden in Cd44&lt;sup>-/-&lt;/sup> Opn&lt;sup>Hep&lt;/sup> Tg mice. Conclusions: Hepatocyte-derived OPN acts as a tumor suppressor at physiological levels by controlling the acute response to DEN and the presence of CSCs, while induction of OPN is pro-tumorigenic. This is primarily due to intracellular events rather that by the secretion of the protein and receptor activation.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-05-18T12:07:33.766Z</modification><creation>2025-05-18T12:07:33.766Z</creation></dates><accession>S-EPMC8948552</accession><cross_references><pubmed>34730871</pubmed><doi>10.1002/hep4.1845</doi></cross_references></HashMap>